2.50
Hdl Handle:
http://hdl.handle.net/10541/74883
Title:
Clinical development of fulvestrant ("Faslodex").
Authors:
Howell, Anthony ( 0000-0002-3879-5991 ) ; Abram, Paul
Abstract:
This paper outlines the development of fulvestrant, the first in a new class of antioestrogen agents with no agonist effects, to be used for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. The role of the oestrogen receptor in breast cancer growth and development and the evolution of pharmacological strategies to manipulate it are also discussed. Preclinical and clinical evidence for the efficacy of fulvestrant are also reviewed, along with the tolerability profile of this agent in relation to other endocrine therapies. Further research will define the role of this exciting new agent in the endocrine treatment of breast cancer.
Affiliation:
CRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uk
Citation:
Clinical development of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S3-9 Cancer Treat. Rev.
Journal:
Cancer Treatment Reviews
Issue Date:
2005
URI:
http://hdl.handle.net/10541/74883
DOI:
10.1016/j.ctrv.2005.08.010
PubMed ID:
16198055
Type:
Article
Language:
en
ISSN:
0305-7372
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorHowell, Anthony-
dc.contributor.authorAbram, Paul-
dc.date.accessioned2009-07-22T10:09:11Z-
dc.date.available2009-07-22T10:09:11Z-
dc.date.issued2005-
dc.identifier.citationClinical development of fulvestrant ("Faslodex"). 2005, 31 Suppl 2:S3-9 Cancer Treat. Rev.en
dc.identifier.issn0305-7372-
dc.identifier.pmid16198055-
dc.identifier.doi10.1016/j.ctrv.2005.08.010-
dc.identifier.urihttp://hdl.handle.net/10541/74883-
dc.description.abstractThis paper outlines the development of fulvestrant, the first in a new class of antioestrogen agents with no agonist effects, to be used for the treatment of hormone receptor-positive advanced breast cancer in postmenopausal women. The role of the oestrogen receptor in breast cancer growth and development and the evolution of pharmacological strategies to manipulate it are also discussed. Preclinical and clinical evidence for the efficacy of fulvestrant are also reviewed, along with the tolerability profile of this agent in relation to other endocrine therapies. Further research will define the role of this exciting new agent in the endocrine treatment of breast cancer.en
dc.language.isoenen
dc.subjectBreast Canceren
dc.subject.meshAged-
dc.subject.meshBreast Neoplasms-
dc.subject.meshClinical Trials as Topic-
dc.subject.meshEstradiol-
dc.subject.meshEstrogen Antagonists-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshMiddle Aged-
dc.subject.meshPostmenopause-
dc.subject.meshReceptors, Estrogen-
dc.subject.meshReceptors, Progesterone-
dc.titleClinical development of fulvestrant ("Faslodex").en
dc.typeArticleen
dc.contributor.departmentCRUK Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. maria.parker@christie-tr.nwest.nhs.uken
dc.identifier.journalCancer Treatment Reviewsen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.